Navigation Links
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Date:12/9/2008

Studies Presented at American Epilepsy Society Annual Meeting

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets comparing tolerability versus levetiracetam immediate release (IR) and reporting on additional dosing schedules. The data were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society (AES) in Seattle.

Keppra XR was approved by the U.S. Food and Drug Administration in September 2008 for use as adjunctive treatment for people with partial-onset seizures who are 16 years of age and older.

"In this new meta-analysis, patients taking Keppra XR experienced fewer nervous system side effects than those taking the same dose of twice daily levetiracetam," said James Zackheim, Medical Director, CNS, UCB. "Keppra XR is the only once-daily, extended-release formulation of levetiracetam, and there is no generic alternative available."

Summary of Keppra XR Data Presented at 2008 AES Annual Meeting

Safety Profile of Levetiracetam Extended Release Compared to Immediate Release: An Indirect Comparison Using a Meta-Analytic Approach

Researchers conducted a meta-analysis of Phase III data to determine whether Keppra XR is associated with any tolerability advantages versus the same daily dose of levetiracetam IR. According to the meta-analysis, patients taking Keppra XR once-daily had lower rates of some adverse events versus levetiracetam IR twice-daily.

-- In terms of overall tolerability, 52.8% of Keppra XR patients reported any adverse event, compared with 79% of patients taking levetiracetam IR.

-- While adverse events associated with levetiracetam IR were also observed with Keppra XR, patients treated with Keppra XR once
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
3. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
4. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
5. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
6. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
10. Opportunities to Highlight Type 1 Diabetes in November
11. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , Chine, 3 juillet 2015 BGI a ... haut débit de l,ADN situé à ... de  l,American College of Pathologists  (Collège des pathologistes ... Hong Kong constituent le ... à recevoir la certification du CAP en Chine, ...
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA ... that its common shares have been approved for listing and ... "EPIX". ESSA will begin trading on NASDAQ on ... the TSX Venture Exchange under the symbol "EPI". ... on the NASDAQ, each of the Company,s outstanding special warrants ...
(Date:7/2/2015)... , July 2, 2015  New product launches ... its leading role in educating thought leaders about new ... can heavily influence how well a new therapy performs ... study from research and consulting leader Best Practices, LLC, ... need to focus on are early stage thought leader ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... 2011 Pharmasset, Inc. (Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral infections, today ... ended December 31, 2010. Financial ... 31, 2010 compared to $0.3 million for the quarter ...
... 7, 2011 BD (Becton, Dickinson and Company) (NYSE: ... company, announced today that it signed a definitive agreement ... company that develops and manufactures personal flow cytometers for ... is expected to close during the third quarter of ...
Cached Medicine Technology:Pharmasset Reports Fiscal First Quarter 2011 Financial Results 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 3Pharmasset Reports Fiscal First Quarter 2011 Financial Results 4Pharmasset Reports Fiscal First Quarter 2011 Financial Results 5Pharmasset Reports Fiscal First Quarter 2011 Financial Results 6BD Announces Agreement to Acquire Accuri Cytometers, Inc. 2BD Announces Agreement to Acquire Accuri Cytometers, Inc. 3
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium ... 2016 Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the ... at the Westin Galleria Dallas. , Designed to take participants from the basic training ...
(Date:7/3/2015)... ... 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce ... Lawsuit Center website. Just as the previous version did, the new website will serve ... updates and ovarian cancer warning information. The site is routinely updated with news articles ...
(Date:7/3/2015)... Deer, Alberta (PRWEB) , ... July 03, 2015 , ... ... host their 24-Hour Train-a-Thon where they provide members of the Red Deer community with ... year’s full day of fitness training, games, food, events and entertainment raised thousands of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by JAMA Internal ... outnumber merely overweight Americans, Samir Becic emphatically declared a war on obesity in the ... now," Becic said. "We must understand the magnitude of this discovery. For that reason, ...
(Date:7/2/2015)... , ... July 02, 2015 , ... In 2012, Patrick Achebe realized that the gift ... alone. He sat down to write his first poem, and three years later he was ... was special and worth sharing with the world. "I have always believed that the best ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
... 10 Winners of the 2007,Award for Excellence in Human ... and Founder of the Health Improvement,Institute., Winners were: ... Online Clinical Trials Principal Investigator Self ... to educate the University,s researchers on the mechanisms by ...
... ALEXANDRIA, Va., Dec. 10 Sen. Max Baucus,(D-Mont.), ... directly,with House leadership on a must-pass Medicare bill ... in his committee last week,but with Congress, scheduled ... Rep. Charles Rangel (D-N.Y.), chair of the House ...
... lymphoma patients with a milder chemotherapy regimen before they ... resulted in long-term complete remission for 45 of 47 ... of Texas M. D. Anderson Cancer Center report at ... Hematology. , The two patients who had relapsed ...
... - Living longer with obesity can lead to both ... hospital, according to two new studies from Purdue University. ... that cite the problems of obesity," said Ken Ferraro, ... which people become obese continues to get younger, we ...
... new treatments, researchers say , , MONDAY, Dec. 10 (HealthDay ... the cancer-susceptibility gene called BRCA1 can cause some breast ... to 20 percent of all breast cancers. BBCs generally ... are almost always associated with hereditary mutations in the ...
... Clinic researchers today presented results of a phase ... first step therapy designed to reduce cancer cells ... showing an improved response over the traditional lenalidomide-dexamethasone ... B. Reeder, M.D., at the American Society of ...
Cached Medicine News:Health News:2007 Human Research Protection Award Recipients Announced 2Health News:NCPA Statement Urging Congress to Include Pharmacy Provisions in Medicare-Medicaid Legislation 2Health News:Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma 2Health News:Living longer with obesity means heavier burden for hospitals 2Health News:Living longer with obesity means heavier burden for hospitals 3Health News:Mutated Suppressor Gene Leads to a Type of Breast Cancer 2Health News:Mutated Suppressor Gene Leads to a Type of Breast Cancer 3
... A to Z Drug Facts produced ... information on thousands of medications. It ... side effect, drug interactions, patient information ... drug reference for physicians, students, residents, ...
... of current natural product information ... with A to Z Drug ... checking. Includes free updates for ... ideal drug reference for physicians, ...
Instant access to drug-drug and drug-food interaction between thousands of brand and generic drugs plus A to Z Drug Facts monographs. Includes free updates for one year....
... Interaction Principles is the number one polypharmacy ... An understanding of drug interactions has become ... publication of the first edition of this ... - coupled with prolonged human life spans ...
Medicine Products: